Sign-up for our newsletter
Pilot & Feasibility
Protocols & Methods
Reagents & Resources
Tissues & Samples
IMPC / KOMP Data
Pilot & Feasibility
Mayo Clinic Rochester
Gastric Emptying and Glycemia in Type 1 Diabetes Mellitus
Approximately 50% of patients with type 1 diabetes mellitus (T1D) have delayed or rapid gastric emptying (GE), which can be measured with scintigraphy or the 13C-Spirulina gastric emptying breath test (GEBT), which is an extensively validated, FDA-approved, office-based test that does not entail radiation. In DM, abnormal GE is usually unrecognized because most patients have limited GI symptoms and GE is not routinely measured. Abnormal GE affects the rate of nutrient absorption; glucagon-like peptide-1 (GLP1) delays GE and improves glycemic control in type 2 DM (T2D), while acceleration of GE increases postprandial glycemia in T1D and T2D. However, the effects of innate (i.e., not pharmacologically mediated) delayed GE on glycemia in T1D are unclear. Our overall long-term objective is to utilize GE to optimize insulin delivery (i.e., dose and timing) with or without artificial pancreas (AP) automated insulin delivery systems and thereby improve glycemic control in DM. Existing models for deconvolving glucose metabolism in DM do not incorporate terms for the rate of GE. Hence, we modified an existing model of oral glucose absorption, added terms for GE to the equations, and incorporated a submodel of insulin diffusion to predict postprandial continuous glucose monitoring (CGM) glucose levels in T1D. Our preliminary findings suggest that subcutaneous glucose values, measured with CGM sensors, for 4 hours after a meal can be accurately predicted with a mathematical model that incorporates fasting glucose, ingested calories, insulin delivery, and GE measured with scintigraphy or a GEBT. The predicted postprandial glucose values approximate closely to actual postprandial CGM glucose values only if the equations use the actual GE values for that patient. This proposal is designed to refine and finalize mathematical models that incorporate GE measured with scintigraphy (Aim 1) and a GEBT (Aim 2) to predict postprandial CGM glucose levels, to assess the closeness of fit between predicted and actual postprandial CGM values, and to establish the importance of GE values to achieving accurate predictions. These models will be developed and validated in existing datasets of T1D patients in whom GE and CGM were simultaneously evaluated. Taken together, we anticipate that these studies will establish that GE, evaluated with scintigraphy or a GEBT, is essential for predicting postprandial glycemia in T1D. If successful, the next steps will be to incorporate GE in insulin hybrid closed loop systems, enabled by our ongoing collaborations with one of the leading AP groups in the world.
No funding program application progress reports found.
No uploaded documents found.
No publications found.
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Gastro-Intestinal (GI) Committee has the principal function of furthering the mission of the consortium with regard to diabetic gastro-intestinal (GI) and liver disease
Curation Flag Information
New comment to be added:
No experiments found.
No strains found.
No models found.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!